Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico
• Treatments: Bevacizumab; Cidofovir; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients diagnosed with recurrent respiratory papillomatosis proven by biopsy.

• Patients with 2 or more previous surgeries for papillomatosis

Exclusion Criteria:

• Patients with heart or renal disease

• Patients who receive another adjuvant therapy